DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Nov 16 (Reuters) - Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi SASY.PA worth up to $1.2 billion, as it seeks to develop DNA-based medicines.
The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly LLY.N, CRISPR Therapeutics CRSP.BN and others
San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions
Seawolf could get milestone payments and royalties
CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much
Seawolf's technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses
The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack
The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis
Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028
But "we'll probably need to raise some additional capital" to reach that stage, Alcamo said